(PHVS) Pharvaris N.V. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(PHVS) Pharvaris N.V. Complete Analysis Pack
Actionable Strategy Starts Here
This Pharvaris N.V. BCG Matrix helps you assess how the company’s products or business units may fit into the classic Stars, Cash Cows, Question Marks, and Dogs framework. What you see on this page is a real preview of the actual analysis, so you can review the content before buying. Purchase the full version to access the complete ready-to-use report.
Stars
0 marketed products
Pharvaris N.V. has 0 marketed products, so it has no true BCG "Star" yet. As a clinical-stage company with no approved therapy, it also has no product revenue, and the portfolio is still in the build phase.
The pipeline is trying to reach that high-share, high-growth zone, but for now the "Stars" box stays empty until one candidate wins approval and gains meaningful market share.
0 commercial sales
Pharvaris N.V. still fits the "0 commercial sales" bucket because it has not reported product revenue from an approved medicine in FY2025. With no marketed asset yet, it has no sales engine to match a true BCG Star. Cash burn remains driven by R&D and clinical trials, so capital is still funding development rather than scale-up.
PHA121 Phase II
PHA121 is Pharvaris N.V.'s lead asset and the clearest Star in its BCG mix: a small-molecule bradykinin B2-receptor antagonist in Phase II for hereditary angioedema. It still needs successful approval before it can turn into a true market leader, so the main value is tied to clinical execution, not current sales. In 2025, the program remains the company's most advanced shot at future revenue.
HAE market unmet need
Hereditary angioedema affects about 1 in 50,000 people worldwide, but the burden is high: repeated swelling attacks can block the airway and disrupt daily life. In a niche market where many patients still rely on injectable or on-demand care, a safe oral therapy could win share fast if it proves durable and well tolerated.
That is why Pharvaris N.V. has star potential: if development succeeds, it could target a clearly unmet need in a specialized, high-value rare-disease franchise.
- Rare disease, high unmet need
- Oral dosing can lift adoption
- Success could drive share gains
Oral platform 3 assets
Pharvaris N.V.’s oral HAE platform has 3 assets, led by oral PHVS719, and it fits a clear unmet need: oral dosing can improve take-up in a rare disease where injectable and on-demand options still dominate. But this is not a BCG "star" yet, because star status needs proof in approval and real use, not just patient convenience.
- Oral route can lift adoption
- HAE remains a small niche market
- Approval and uptake still decide value
- Pipeline strength, not sales, drives the case
Pharvaris Has No FY2025 Stars Yet—PHA121 Is Still a Phase II Bet
Pharvaris N.V. has no true BCG "Stars" in FY2025: it reported 0 marketed products and 0 product revenue. PHA121 is the closest future Star, but it is still only in Phase II, so value depends on approval and uptake, not current sales. Rare-disease demand is real, but the market is still pre-commercial.
| Metric | FY2025 |
|---|---|
| Marketed products | 0 |
| Product revenue | 0 |
| Lead asset | PHA121 |
| Development stage | Phase II |
What is included in the product
Detailed Word Document
Pharvaris N.V. BCG Matrix shows portfolio positioning, highlighting Stars, Cash Cows, Question Marks, and Dogs for invest-or-divest decisions.
Editable Excel File
Quick BCG Matrix snapshot of Pharvaris N.V. to simplify portfolio pain points and decision-making.
Reference Sources
Pharvaris N.V. Reference Sources provide a clear, traceable evidence trail that boosts credibility and speeds smarter decisions.
Cash Cows
0 approved medicines
Pharvaris N.V. has 0 approved medicines, so it does not yet have a mature cash-cow franchise. Cash cows need an established, low-growth, high-share market position, and Pharvaris has not reached that point. With no commercial product sales, the segment still depends on clinical progress and external funding, not steady operating cash flow.
0 recurring product revenue
Pharvaris N.V. has no disclosed recurring product revenue because it has no marketed brand, so there is no cash cow to milk today. In its latest FY2025 reporting, product sales remained at $0, and funding still came from financing activities rather than operating cash flow. That leaves this BCG bucket empty for now, with value tied to pipeline progress, not recurring sales.
0 royalty streams
Pharvaris N.V. has disclosed no material licensing royalty revenue, so this Cash Cow is effectively 0. That means there is no steady royalty engine to fund operations, which removes a classic BCG cash-cow trait. The balance sheet still depends on capital raises and tight spend control to keep R&D funded.
0 mature market share
Pharvaris N.V. has 0% mature-market share because it has no approved, marketed product yet; cash cows need scale in a stable market, and Pharvaris is still paying for clinical development. In its latest filings, the Company reported no product revenue, so there is no cash-flow base to classify it as a cash cow. Any share must first be won in Phase 3 and then at launch.
- No marketed product
- Market share: 0%
- No product revenue
- Share must be earned in trials
0 dividend support
Pharvaris N.V. has no dividend support in 2025/2026 because it still has no product sales and remains in active development. The company is using cash for clinical work and regulatory value creation, so capital preservation matters more than cash harvest.
That profile fits a Cash Cow only in a negative sense: there is no free cash flow to fund payouts, and retained cash is needed to extend runway and support the pipeline.
- No operating dividend capacity
- Cash is for trials and filings
- Preserve capital, do not harvest
Pharvaris Has No Cash Cow Yet in FY2025/2026
Pharvaris N.V. has no Cash Cow in FY2025/2026: it reported $0 product sales, no approved medicines, and 0% mature-market share. With no recurring royalty or operating cash flow, the Company is still funding R&D from financing, not harvesting cash.
| Metric | FY2025/2026 |
|---|---|
| Product revenue | $0 |
| Approved medicines | 0 |
| Mature-market share | 0% |
| Royalty income | $0 |
Full Version Awaits
Pharvaris N.V. Reference Sources
The Pharvaris N.V. BCG Matrix preview you see is the exact document you’ll receive after purchase. It’s the full, ready-to-use file—no demo content, no watermarks, and no hidden changes. Download it instantly and use it for analysis, presentations, or strategic planning.
Dogs
0 legacy brands
Pharvaris N.V. has 0 legacy brands and no commercial product sales, so there is no obvious "dog" weighing on growth. In BCG terms, the portfolio is still pre-revenue, not a mature mix with declining cash cows or dogs. That matters: the drag on value is not old brands, but the cost of advancing a pipeline that has yet to launch.
0 low-share mature products
Dogs do not really fit Pharvaris N.V. here: as a clinical-stage company, it had no commercial sales in FY2025, so there is no mature product with low share to classify. The core risk is pipeline and approval risk, not product obsolescence; cash burn and trial outcomes matter more than market share.
0 divestiture candidates
Pharvaris N.V. has 0 divestiture candidates in Dogs because its core HAE pipeline has no marketed asset to sell. The company is still in development mode, so decisions are about advancing or stopping candidates, not spinning off a low-value product line. As of the latest reported 2025 updates, that means no obvious dog asset exists to divest.
0 break-even units
Pharvaris N.V. has no unit that only breaks even: it still reported zero commercial revenue in FY2025, while R&D kept funding late-stage hereditary angioedema programs. So the cash use comes from development work, not a mature franchise carrying fixed overhead. That is pre-commercial, not a dog business.
- No break-even unit exists
- FY2025 revenue stayed at zero
- R&D is the main cash use
- Profile is pre-commercial, not dog
0 turnaround stories
Pharvaris N.V. has 0 turnaround stories in Dogs because it is not a weak commercial asset that needs a costly fix; it is a clinical-stage company whose value depends on trial readouts. The real risk is attrition: if PHARVARIS assets miss endpoints, the downside is fast and direct, not gradual repair. In BCG terms, this is a binary clinical bet, not a turnaround case.
- Clinical success or failure drives value
- No commercial turnaround to execute
- Attrition risk matters more than repair
Pharvaris Has No “Dog” Products—Only Pipeline Risk
Pharvaris N.V. has no clear "Dogs" in FY2025 because it reported zero commercial revenue and has no mature, low-share product to classify. Its value is still tied to HAE pipeline execution, while R&D remains the main cash use.
So the "Dog" bucket is effectively empty: there is no break-even legacy unit, no divestiture candidate, and no turnaround asset. Risk is binary trial and approval risk, not weak product decline.
Question Marks
PHA121 Phase II
PHA121 is Pharvaris N.V.'s lead small molecule bradykinin B2-receptor antagonist, and it is in Phase II for hereditary angioedema. Its clinical path matters because the HAE market remains small but high value, with approved prophylaxis and on-demand therapies still leaving room for better oral options. If efficacy and safety stay strong, PHA121 is the clearest candidate to move from Question Mark to future Star.
PHVS416 Phase II
PHVS416 is Pharvaris N.V.’s Phase II, on-demand soft capsule for acute hereditary angioedema attacks, so it fits the Question Mark cell: high-growth niche, no market share yet.
That matters because acute HAE still needs fast, convenient treatment, and an oral option could compete with injectable rescue drugs if Phase II data stay strong.
For now, it is an R&D bet, not a revenue driver, so the upside is real but the execution risk is just as high.
PHVS719 Phase I
PHVS719 is still a Phase I extended-release prophylactic tablet for hereditary angioedema, so both clinical readout risk and commercial visibility remain low. Early-stage assets like this sit in the Question Marks bucket because they need proof of safety and dose control before value can scale. If PHVS719 advances, the upside can be large, but right now the probability-adjusted value is still uncertain.
HAE on-demand use
HAE on-demand use is clinically important and commercially attractive, with attacks often lasting 2-5 days and driving urgent rescue treatment. Pharvaris is targeting this segment with an oral candidate, which could matter because current on-demand care is still dominated by injections. Until launch, Pharvaris’ share is 0%, so it remains a Question Mark.
High unmet need, fast treatment value
Oral route could improve uptake
No sales yet, so share stays zero
HAE prophylaxis use
HAE prophylaxis is Pharvaris N.V.'s growth call option, but it is still a development-stage bet with no approved tablet yet. If the oral drug shows strong long-term prevention, it could support chronic use and a larger, steadier revenue stream than rescue care. Adoption stays uncertain until efficacy, safety, and payer coverage are proven.
- Growth target, not core cash flow
- Chronic use needs clear prevention data
- Adoption risk stays high today
Pharvaris’ Pipeline: Early HAE Bets, Led by PHA121
Pharvaris N.V.'s Question Marks are PHA121, PHVS416, and PHVS719: all are still pre-revenue, with 0% market share. HAE attacks can last 2-5 days, so an oral option could win fast uptake, but each asset still faces clinical, safety, and payer risk. PHA121 in Phase II is the main value driver; PHVS416 and PHVS719 remain earlier-stage bets.
| Asset | Status | Share |
|---|---|---|
| PHA121 | Phase II | 0% |
| PHVS416 | Phase II | 0% |
| PHVS719 | Phase I | 0% |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.